Clinical value of Aescuven forte in preventing ovarian hyperstimulation syndrome
10.3760/cma.j.cn101441-20200214-00064
- VernacularTitle:迈之灵预防卵巢过度刺激综合征的临床价值
- Author:
Tingting LI
1
;
Wanshan ZHU
;
Bo WANG
;
Cong FANG
Author Information
1. 中山大学附属第六医院生殖医学研究中心，广州510655
- Publication Type:Journal Article
- Keywords:
Aescuven forte;
Fertilization in vitro;
Embryo transfer;
Ovarian hyperstimulation syndrome
- From:
Chinese Journal of Reproduction and Contraception
2021;41(2):149-153
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of oral Aescuven forte on the incidence and severity of ovarian hyperstimulation syndrome (OHSS).Methods:A total of 100 patients who cancelled transplantation after oocyte retrieval for in vitro fertilization-embryo transfer assisted reproduction due to high risk of OHSS between February 2018 and October 2019 in Reproductive Medicine Research Center, the Sixth Affiliated Hospital, Sun Yat-Sen University were randomized into two groups in this prospective randomized controlled trial. The patients in experimental group (50 cases) received 300 mg, bid of Aescuven forte orally for 10 d after oocyte retrieval, while control group (50 cases) did not receive Aescuven forte; otherwise, both groups underwent the same treatments. The incidence rate and severity of OHSS were compared between the two groups. Results:No significant differences were found in variables such as age, body mass index (BMI), anti-Müllerian hormone (AMH) level, total dosage of gonadotropin (Gn) used, and the number of retrieved oocytes between the two groups ( P>0.05). The incidence rate of moderate to severe OHSS in experimental group and control group was 4.00% (2/50) and 18.00% (9/50), respectively, with a statistically significant difference ( P=0.025). Control group included 3 cases of paracentesis due to ascites, while experimental group did not include any cases of paracentesis or severe OHSS. Conclusion:Oral administration of Aescuven forte effectively prevent the incidence of moderate to severe OHSS in high-risk patients and reduced the severity of OHSS.
